DoD Tuberous Sclerosis Complex Exploration Hypothesis Development Award
The mission of the TSCRP is to encourage innovative research aimed at understanding the pathogenesis and manifestations of TSC to improve the lives of individuals with TSC. Within this context, the FY13 TSCRP encourages applications that address one or more of these vital program Focus Areas: • Genetic, epigenetic, and non-genetic modifiers of TSC. • Preclinical models and therapeutic strategies (e.g., cytotoxic agents, combination therapies). • Biomarkers for early detection, prognosis, and prediction of treatment outcomes (such as serum markers, imaging, electrophysiology, prenatal testing, and pharmacogenetics). • Impact of TSC manifestations in adults (e.g., care management, age-specific pathogenesis, epidemiology, renal, reproductive issues, and lymphangioleiomyomatosis [LAM]). • Long-term benefits and effects of mTOR inhibitors or other agents. • Novel strategies for diagnosis, treatment, and prevention of TSC manifestations including those geared toward early identification and intervention. • Cellular and molecular mechanisms of TSC and LAM pathogenesis. • Causes and treatment of epilepsy in TSC. • Causes and treatment of TSC-associated neurocognitive disorders including cognitive impairment, and psychiatric, behavioral, and sleep disorders. The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The proposed research project should provide initial principles of an innovative question/concept, and results of studies conducted through this award should provide the scientific rationale upon which a new hypothesis may be developed. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. The presentation of preliminary or published data is encouraged, but not required.
Office: U.S. Army Medical Research Acquisition Activity
301-682-5507
help@cdmrp.org
